Today Stories

Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites (“the Company”), an international medical devices company that engineers, manufactures and markets leading products for use in infection management in bone and soft tissue. As part of the transaction TA, Biocomposites’ majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites’ management. The transaction gives TA and Novo Holdings shared control of Biocomposites. Headqua…

The Cambridge Festival is returning from March 19 to April 4 with a series of events that bring together cutting-edge health research and the latest innovations in medical science. This year's health theme comes at a pivotal moment, as global health challenges such as ageing populations, chronic disease and cancer diagnosis continue to drive scientific inquiry and public debate. Against this backdrop, the Festival provides a platform to engage the public with pioneering research from some of the brightest minds in health and medicine. The Festival offers almost 400 mostly free events across multiple themes, including environment, society, and discovery, with health research at the forefront. Visitors can attend more than 130 events focussed on this theme, many designed to demystify the sci…

Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America The company's plans represent the largest pharmaceutical manufacturing investment in U.S. history  INDIANAPOLIS, Feb. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. This brings the company's total U.S. capital expansion commitments to more than $50 billion since 2020. Three of the future U.S. sites announced today will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of…

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever  GALWAY, Ireland, Feb. 24, 2025 /PRNewswire(opens new window)/ -- For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI). There is no cure for debilitating neurological conditions like Parkinson's, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS is similar to a ca…

RESEARCH TRIANGLE PARK, N.C. – February 24, 2025 – IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questions. Using a conversational interface with advanced data science, it makes complex analytics accessible to a wide variety of users and provides near real-time insights. IQVIA AI Assistant builds upon IQVIA’s decade of experience in artificial intelligence and developing Healthcare-grade AI™, a pro…

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST). As announced previously1, the acquisition includes lead molecule IDRX-42, an investigational, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve outcomes for patients with GIST. IDRX-42 has demonstrated activity against all clinically relevant primary and secondary KIT mutations, a key medical need in current GIST treatment. GIST typically presents in the gastrointestinal (GI) tract with 80% of cases driven by mutations in the KIT gene that lead to the growth, proliferation, and survival of tumour cells…

Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditions Combined with an innovative, high throughput sensor module, SBX uses expanded synthetic molecules to determine the DNA sequence of a target molecule, creating an ultra-rapid, scalable and flexible technology Reducing the time from sample to genome from days to hours, this novel approach could significantly speed up genomic research, as well as translational and clinical applications in the years to come Basel, 20 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology…

BioMed X Institute, in collaboration with the Government of Barbados and the European Commission, is launching BioMed X Barbados, a new research initiative focused on better treatment of cardiometabolic diseases in individuals of African descent. Heidelberg, Germany / Bridgetown, Barbados – February 20, 2025. BioMed X Institute is proud to announce a partnership with the Government of Barbados focused on advancing the treatment of cardiometabolic diseases in individuals of African descent. This initiative, supported by the European Commission’s PharmaNext program, will begin with a two-year pilot project focusing on molecular characterization of patients in Barbados. Cardiometabolic diseases, including type 2 diabetes, hypertension, obesity, and cardiovascular conditions, continue to ris…

Kelso Pharma, the growing specialty pharma business backed by Apposite Capital, the healthcare specialist private equity investor, today (19 February 2025) announces the acquisition of the UK pharma business, ALTURiX Holdings Limited (ALTURiX). The transaction marks a significant step towards Kelso’s vision of building a specialty pharma business of scale in the UK and ultimately across Europe.  The acquisition will be complementary, with Kelso Pharma and ALTURiX sharing a common philosophy of supplying branded specialty medicines that provide patient benefits and a reduced cost burden to the NHS. ALTURiX has seven branded medicines in the UK market today, driving double digit topline revenue growth. These are in the therapeutic areas of: Central nervous system Respiratory disease Endocri…

Recent studies suggest current approach to current cardiovascular risk assessment is inadequate / A more personalized approach offers new opportunities for positive intervention / Affordable, accessible tools like ultrasound increase access to assessing cardiovascular risk Basel, Switzerland, February 18, 2025 – With the recent 125th anniversary of aspirin’s discovery, new research is shedding light on innovative approaches to cardiovascular health that can increase access to cardiovascular disease prevention through more precise and individualized care. A series of recent studies emphasize the importance of viewing cardiovascular risk as a continuum and utilizing affordable and easily available tools like carotid ultrasound to better assess individual patient risk, ther…

CAMBRIDGE, UK: Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients. The test identifies the presence or absence of cancerous cells, signs of early and late-stage cancer, whether it is slow or aggressive as well as genetic and hereditary risks in the patient. The new test involves studying the most comprehensive combination of clinically-validated prostate-related biomarkers currently known, in both blood and urine samples. The interpretation of these biomarkers using a proprietary AI-driven algorithm highlights early signs of cancer and characteristic features that can guide treatment selection. There are 55,000 new cases of prostate cancer in th…

Cancer cells have to escape from the scaffolding that surrounds tumours – a structure called the extracellular matrix – in order to spread Researchers discovered that the layout of the matrix drives cancer cells to change their shape, increasing their ability to spread Patients with melanoma tumours with these features had shorter survival times The findings could help doctors spot which tumours are likely to be aggressive and cause metastatic cancer This opens new avenues for treating cancer before it spreads – by targeting the surroundings of the tumour, instead of the cancer cell itself Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body. New research, published in Nature Communications, reveals how ca…

Sandwich, Kent, UK / 13 February 2025 /  Eleven early-stage companies working in oncology have started ‘Discovery Spark’, a free seven week development programme  hosted by leading science and innovation campus Discovery Park, in Sandwich, Kent. Designed to offer start-ups the skills and tools to lay healthy foundations in their business, refine their commercial strategy and achieve investor readiness, all 11 businesses will be put through their paces to enable future success and growth. Supported by Capital Enterprise Network, Cancer Tech Accelerator, NHS Kent and Medway Cancer Alliance and the University of Kent, Discovery Park’s latest Discovery Spark programme has an oncology theme. The 11 entrepreneurial businesses securing a coveted spot on this cohort and looking to advance their or…

The company, with two endocrinology products approved by both the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), is developing additional endocrinology and oncology therapies, and has formed strategic partnerships in other indications and markets. The development of these drugs is based on the innovative TransCon® technology platform, which combines the efficacy of the parent drug, whose biology is known, with the benefits of prodrug and a sustained release mechanisms. London, United Kingdom, February 6th 2024 – Ascendis Pharma UK, a subsidiary of the global biopharmaceutical company with a portfolio of products and product candidates specialising in rare endocrine diseases, has opened a UK office and appointed a senior management team led by UK Genera…

The Apex is the first phase of a one million sq ft of purpose-built life sciences space in King’s Cross’ Knowledge Quarter The London BioScience Innovation Centre (LBIC) signed a lease on 39,000 sq ft or c. 35% of the space in the building The Francis Crick Institute is collaborating on 52,000 sq ft of space in the building 11 February 2025, London – Reef Group (“Reef”), the leading property development and investment specialist, and BlackRock Real Estate, have completed The Apex, the first laboratory building at TRIBECA, London’s largest purpose-built life science campus. The Apex is the first phase of the development and comprises over 110,000 sq ft of laboratory and office space, set over six floors. As a purpose-built life sciences campus, The Apex and subsequent phases of TRIBECA ha…

[Dublin, 10th February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global markets. The new facilities, located in Raleigh, USA, Lelystad, Netherlands, and Dublin, Ireland, reflect Uniphar’s commitment to enhancing its logistics and distribution capabilities within global pharmaceutical and healthcare sectors. With 57 years’ industry experience, Uniphar’s new facilities position the company to support pharmaceutical and biotech companies more effectively, offering comprehensive solutions that cover the entire product lifecycle. The new locations aim to ensure the timely delivery of critical therapies to patients worldwide, whil…

The research of BioMed X team EDC – Extrachromosomal DNA in Cancer – has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies. Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership with Merck. The data generated by this project has been acquired by Merck for further development, potentially leading to new therapeutic approaches in precision oncology. Launched in August 2022, the collaboration aimed to unravel the mechanisms behind the formation, propagation, and impact of ecDNA in cancer cells using state-of-the-art single-cell screening and spatial technolog…

Bracknell, UK. 4th February 2025: PharmiWeb.Jobs, the leading global life sciences job board, is excited to announce that the platform has now reached over 600,000 registered jobseekers, globally. This remarkable milestone signifies the team’s commitment to connecting life science professionals with the best career opportunities in the industry, whilst helping recruiters and hiring managers locate the top talent they need to drive their organisations forward. “Hitting 600,000 registered jobseekers is a huge milestone for PharmiWeb and a real testament to the trust life science professionals place in our platform,” said Vincent Lody, Managing Director of PharmiWeb. “Our goal has always been to connect talented people with the right opportunities, and it’s fantastic to see our community grow…

RESEARCH TRIANGLE PARK, N.C. – February 4, 2025 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World’s Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on four key attributes — innovation, global competitiveness, people management and use of corporate assets. “We are deeply honored to be recognized for the fourth year in a row as number one on the World’s Most Admired Companies list for our category, and to be named to the list for the eighth consecuti…

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company’s network MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and d…